Vidaza
Nice rejects Celgene’s drug to treat blood cancer
June 24, 2016Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer
The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …
Celgene’s Vidaza earns wider approval
November 2, 2015Sales and Marketing Celgene, European Commission, Vidaza, acute myeloid leukaemia, azacitidine, leukaemia
Swiss firm Celgene has been given approval by the European Commission to extend its marketing authorisation for the cancer treatment …
Vidaza patient access scheme sways NICE
February 17, 2011Sales and Marketing Celgene, NICE, Vidaza
Celgene’s Vidaza has been recommended by NICE in final draft guidance issued today. Vidaza (azacitidine) is recommended as a treatment …
Vidaza too costly for NICE
March 8, 2010Sales and Marketing Celgene, NICE, Vidaza
NICE has rejected Celgene’s Vidaza for use on the NHS to treat the rare bone marrow disease myelodysplastic syndrome. The …
First-in-class cancer treatment Vidaza launched
March 3, 2009Research and Development Vidaza
Vidaza, an innovative new treatment for a number of hard-to-treat blood cancers, has been launched in the UK by Celgene. …
